Alan W. Varley
University of Texas Southwestern Medical Center
15 Papers
168 Citations
Alan W. Varley is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Acyloxyacyl hydrolase & Lipopolysaccharide. The author has an hindex of 12, co-authored 15 publications.
Chat about Author
Papers
Inflammation-induced recombinant protein expression in vivo using promoters from acute-phase protein genes
TL;DR: It is reported that promoters for two murine acute-phase protein genes, complement factor 3 (C3) and serum amyloid A3 (SAA3), can increase recombinant protein expression in response to inflammatory stimuli in vivo.
Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.
TL;DR: The liver’s ability to take up and deacylate free LPS aggregates and the LPS in preformed LPS-high density lipoprotein (HDL) complexes is compared and KCs and AOAH play important roles in clearing and catabolizing both free and HDL-bound radiolabeled LPS.
Persistently active microbial molecules prolong innate immune tolerance in vivo.
TL;DR: It is shown that prolonged macrophage reprogramming is maintained in vivo by the persistence of stimulatory LPS molecules within the cells' in vivo environment, where naïve cells can acquire LPS via cell-cell contact or from the extracellular fluid.
A two-component expression system that responds to inflammatory stimuli in vivo
TL;DR: A two-component expression construct is described in which the murine complement factor 3 (C3) promoter regulates production of the human immunodeficiency virus (HIV) transactivator of transcription (Tat) and the Tat protein then stimulates protein expression from genes inserted downstream of the the HIV promoter.
40
Physiologically responsive gene therapy.
Alan W. Varley,Robert S. Munford +1 more
TL;DR: The goal of physiologically responsive gene therapy is to allow a host's endogenous regulatory mechanisms to control the production of therapeutic proteins (effectors).
37